BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|16|7|606-617

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.16, Iss.7, 2016-08, pp. : 606-617

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advances in the Treatment of Triple-negative Early Breast Cancer

By  

Medicinal Chemistry, Vol. 12, Iss. 3, 2016-05 ,pp. : 268-272

Bentham Science Publishers

Access to resources Recommend Favorite

Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment

By  

Current Drug Delivery, Vol. 15, Iss. 3, 2018-03 ,pp. : 406-416

Bentham Science Publishers

Access to resources Recommend Favorite

Triple-Negative Breast Cancer: Epidemiology and Management Options

By Dawood Shaheenah  

Drugs, Vol. 70, Iss. 17, 2010-12 ,pp. : 2247-2258

Adis International

Access to resources Recommend Favorite

Subtyping of triple-negative breast cancer: Implications for therapy

By Abramson Vandana G.   Lehmann Brian D.   Ballinger Tarah J.   Pietenpol Jennifer A.  

Cancer, Vol. 121, Iss. 1, 2015-01 ,pp. : 8-16

Blackwell Publishing

Access to resources Recommend Favorite

Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer

By  

Current Drug Targets, Vol. 19, Iss. 1, 2018-01 ,pp. : 70-80

Bentham Science Publishers

Access to resources Recommend Favorite